TauscheAKRichterKGrässlerAHänselSRochBSchröderHE.Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis. 2004;63:1351-1352.
2.
AllenKCChamplainAHCotliarJAet al. Risk of anaphylaxis with repeated courses of rasburicase: a research on adverse drug events and reports (RADAR) project. Drug Saf. 2015;38:183-187. doi:10.1007/s40264-014-0255-7
3.
HowardSCJonesDPPuiCH.The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854. doi:10.1056/NEJMra0904569
4.
LiotéFBardinT.Traitement de la goute. Rev Rhum. 2007;74:160-167.
5.
SchellekensH.Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(suppl 6):vi3-vi9. doi:10.1093/ndt/gfh1092
6.
IshizawaKOguraMHamaguchiMet al. Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci. 2009;100:357-362. doi:10.1111/j.1349-7006.2008.01047.x
